Japan · Delayed Price · Currency is JPY MedRx Company Description
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan.
The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer’s disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain.
MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
| Country | Japan |
| Founded | 2002 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Yonehiro Matsumura |
Contact Details
Address: 431-7 Nishiyama Higashikagawa, 769-2712 Japan | |
| Phone | 81 8 7923 3071 |
| Website | medrx.co.jp |
Stock Details
| Ticker Symbol | 4586 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3921220004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yonehiro Matsumura | Chief Executive Officer |